Is Biodentine, as successful as, mineral trioxide aggregate for pulpotomy of primary molars? A split-mouth clinical trial

BackgroundDespite the clinical and radiographic success of mineral trioxide aggregate (MTA) pulpotomy in primary molars, it does not gain much clinicians acceptance regarding manipulation difficulties.AimThis study aims to assess success rates of Biodentine and MTA used as pulpotomy agents in human primary molars, both clinically and radiographically.Patients and methodsA split-mouth controlled clinical trial was carried out on 21 healthy, 3–7-year old children, with 42 pairs (84 molars) of contralateral mandibular primary molars indicated for pulpotomy. One paired tooth in one side was designated to Biodentine (group 1) and the other side for MTA (group 2) as a pulp medicament. All pulpotomized teeth were finally restored with stainless-steel crowns. Patients were monitored clinically and radiographically at 1, 3, 6, and 12 months.ResultsFor all the patients available for the follow up appointments, Biodentine and MTA showed 100% success rate both clinically and radiographically.ConclusionBiodentine and MTA are highly recommended as pulpotomy medicaments in primary molars.